免疫疗法
肺癌
德尔菲
医学
德尔菲法
肿瘤科
重症监护医学
癌症
内科学
计算机科学
人工智能
操作系统
作者
Giovanni Luca Ceresoli,Giulio Rossi,Francesco Agustoni,Lucia Bonomi,Paolo Borghetti,Alessandra Bulotta,Clelia Casartelli,Giulio Cerea,Francesca Colonese,Ester Del Signore,Giovanna Finocchiaro,Letizia Gianoncelli,Salvatore Grisanti,M. Maiolani,Fabio Pagni,Claudia Proto,Erika Rijavec,Isabella Vittimberga,Stefano Arcangeli,Andrea Riccardo Filippi
标识
DOI:10.1016/j.critrevonc.2023.104247
摘要
Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements. 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy. While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI